Following its privatization in October 2024 by Bansk Group for $1.5 billion, PetIQ operates as an independent branded pet health company with dual revenue streams: consumer products (flea/tick control, medications, wellness items) and direct veterinary services. The company leverages its manufacturing capabilities and retail partnerships to maintain market position in the growing pet health and wellness sector.
Cyborg Score Rationale
PetIQ demonstrates strong operational fundamentals with established manufacturing infrastructure, diversified revenue streams, and significant market presence. As a private equity-backed entity post-acquisition, the company benefits from dedicated capital investment and operational independence under experienced leadership.
Top Insights
(October 2024) Acquired by Bansk Group for $1.5 billion and transitioned to private ownership
Operates dual business model: branded/distributed pet medications via retail/e-commerce plus veterinary services in 2,600+ mobile clinics across 39 states
Maintains manufacturing facilities at three U.S. locations (Omaha, Springville, Daytona Beach) with lean manufacturing expertise
Positioned in growing pet wellness market with focus on accessible, affordable alternatives to traditional veterinary care
Named Competitors
Chewy — E-commerce pet supplies and medications
VCA Hospitals — Veterinary hospital networks and pet care services
Rover — Pet services platform and veterinary telehealth
Recent Developments
(October 2024) Completed acquisition by Bansk Group, delisted from Nasdaq, became privately held company
Open the full interactive PetIQ, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.